Bissonnette, Robert http://orcid.org/0000-0001-5927-6587
Call, Robert S.
Raoof, Tooraj
Zhu, Zhaoyin
Yeleswaram, Swamy
Gong, Xiaohua http://orcid.org/0000-0002-3437-4399
Lee, Mark
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis
https://doi.org/10.1007/s40257-022-00690-3
Funding for this research was provided by:
Incyte Corporation
Article History
Accepted: 22 March 2022
First Online: 4 April 2022
Declarations
:
: This study was funded by Incyte Corporation (Wilmington, DE, USA).
: RB has served as an advisory board member, consultant, speaker, and/or investigator and received honoraria and/or grants from AbbVie, Arcutis, Arena Pharma, Aristea, Asana BioSciences, Bellus Health, Bluefin Biomedicine, Boehringer Ingelheim, CARA, Dermavant, Eli Lilly, EMD Serono, Evidera, Galderma, GlaxoSmithKline, Incyte, Inmagene Bio, Kiniksa, Kyowa Kirin, LEO Pharma, Novan, Pfizer, Ralexar, RAPT Therapeutics, Regeneron, Respivant, Sanofi-Genzyme, Sienna, Target RWE, and Vyne Therapeutics and is an employee and shareholder of Innovaderm Research. RSC has served as a principal investigator for Incyte Corporation. TR has served as an investigator for AbbVie, Arcutis, AstraZeneca, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Galderma, GlaxoSmithKline, Eli Lilly, Incyte Corporation, Janssen, LEO Pharma, Pfizer, Regeneron, Sanofi-Genzyme, and UCB Biopharma. ZZ was an employee and shareholder of Incyte Corporation at the time of this study. SY and XG are employees and shareholders of Incyte Corporation. ML is an investigator for AbbVie, Arcutis, AstraZeneca, Bausch Health, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly, Incyte Corporation, Janssen, Kiniksa Pharmaceuticals, LEO Pharma, Pfizer, RAPT Therapeutics, Reistone Biopharma, Regeneron, and UCB Biopharma.
: This study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The protocols were approved by the relevant institutional review board or ethics committee at each study site.
: Written informed consent/assent was provided by all patients before enrollment.
: Written informed consent/assent was provided by all patients before enrollment.
: Incyte Corporation (Wilmington, DE, USA) is committed to data sharing that advances science and medicine while protecting patient privacy. Qualified external scientific researchers may request anonymized datasets owned by Incyte for the purpose of conducting legitimate scientific research. Researchers may request anonymized datasets from any interventional study (except phase I studies) for which the product and indication have been approved on or after 1 January, 2020 in at least one major market (e.g., USA, European Union, Japan). Data will be available for request after the primary publication or 2 years after the study has ended. Information on Incyte’s clinical trial data sharing policy and instructions for submitting clinical trial data requests are available at: ExternalRef removed.
: Not applicable.
: RB contributed to the study design and data collection. RSC and TR contributed to data collection. ZZ and SY contributed to the study design and data analysis. XG contributed to data analysis. ML contributed to the study design. All authors contributed to drafting and critical appraisal of the manuscript and approved the final version for submission.